DSGN Stock Analysis: Buy, Sell, or Hold?
DSGN - Design Therapeutics, Inc. Common Stock
$15.03
-0.50 (-3.22%)
âŧ
5d:
-1.44%
30d:
+10.76%
90d:
+39.68%
WAIT
LOW Confidence
Analysis Updated: Sep 3, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When DSGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: DSGN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: DSGN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: DSGN is currently trading at $15.03, which is considered slightly high relative to its 30-day fair value range of $12.32 to $15.26.
Technical Outlook: Technically, DSGN is in a uptrend. Immediate support is located at $14.38, while resistance sits at $15.96. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: DSGN scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.00 (+39.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DSGN is in a uptrend. Immediate support is located at $14.38, while resistance sits at $15.96. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: DSGN scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.00 (+39.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$12.32 -
$15.26
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
36.8%
All Signals
- BEARISH: Weak technical setup (29/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 39.7% below Wall St target ($21.00)
- WARNING: Composite score 46/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$12.32 -
$15.26
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$14.38
Resistance Level
$15.96
Current Trend
Uptrend
Technical data as of
Sep 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.44
Wall Street Target
$21.00
(+39.7%)
Share & Embed Analysis
Last updated: September 04, 2026 3:10 AM ET
Data refreshes hourly during market hours. Next update: 4:10 AM
Data refreshes hourly during market hours. Next update: 4:10 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DSGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 61 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 47 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$563 | 35 SELL |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
